Takeda Can't Duck Generic-Drug Delay Suit At 2nd Circ.
The Second Circuit found on Wednesday that Takeda cannot upend a New York federal judge's decision to preserve antitrust claims that it delayed entry of generic alternatives to diabetes treatment Actos,...To view the full article, register now.
Already a subscriber? Click here to view full article